Ignite Creation Date:
2024-05-06 @ 7:14 PM
Last Modification Date:
2024-10-26 @ 3:03 PM
Study NCT ID:
NCT05942807
Status:
RECRUITING
Last Update Posted:
2023-07-12
First Post:
2023-03-20
Brief Title:
Observational Monocentric Study on Biliary Tract Cancer BABEL
Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Organization:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study Overview
Official Title:
The Prognostic and Predictive Role of Clinical Biochemical Pathological and Molecular Characteristics of Patients With Biliary Tract Cancer an Observational Monocentric Study BABEL
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BABEL
Brief Summary:
BABEL is an observational single-center prospective study about patients affected by biliary tract cancers BTC treated at the Medical Oncology Unit of the FPUAG - IRCCS
Detailed Description:
BABEL is an observational single-center prospective study with an historical cohort Study population is represented by patients affected by biliary tract cancers BTC treated at the Medical Oncology Unit of the FPUAG - IRCCS The study involves an historical cohort and a prospective cohort Primary aim of the study is to associate BTC patients overall survival with IDH12 mutations in order to confirm the prognostic role of these genes both metastatic and resectable disease setting The secondary aims are to correlate FGFR mutations and overall survival of BTC patients and to find new clinical and molecular characteristics linked with survival and response to treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None